# Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

> **NCT01874353** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 327 (actual)

## Conditions studied

- Platinum Sensitive
- BRCA Mutated
- Relapsed Ovarian Cancer
- Following Complete or Partial Response to Platinum Based Chemotherapy

## Interventions

- **DRUG:** Olaparib 300mg tablets
- **DRUG:** Placebo to match olaparib 300mg

## Key facts

- **NCT ID:** NCT01874353
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-09-03
- **Primary completion:** 2016-09-19
- **Final completion:** 2025-12-31
- **Target enrollment:** 327 (ACTUAL)
- **Last updated:** 2025-08-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01874353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01874353, "Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01874353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*